What are the recommended dosing, schedule, contraindications, and alternative regimen for PCV20 (20‑valent pneumococcal conjugate vaccine) in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

PCV20 Dosing and Recommendations for Adults

Administer a single 0.5 mL intramuscular dose of PCV20 to all adults aged ≥50 years who have not previously received any pneumococcal conjugate vaccine, and to adults aged 19-49 years with immunocompromising conditions, chronic medical conditions, CSF leak, or cochlear implant. 1, 2

Dosing Schedule by Age and Risk Group

Adults ≥65 Years (Vaccine-Naïve or PCV7 Only)

  • Single dose of PCV20 (preferred as standalone option)
  • Alternative: PCV15 followed by PPSV23 ≥1 year later (minimum 8 weeks for immunocompromised/CSF leak/cochlear implant) 1

Adults ≥50 Years (New 2024 Expansion)

  • Single dose of PCV20 for all PCV-naïve adults in this age group
  • This represents a significant expansion from the previous ≥65 years recommendation 2

Adults 19-64 Years with High-Risk Conditions

Immunocompromising conditions (chronic renal failure, nephrotic syndrome, HIV, malignancy, immunosuppression, asplenia, sickle cell disease, transplant recipients):

  • Vaccine-naïve: Single dose PCV20, OR PCV15 followed by PPSV23 ≥8 weeks later 1, 3
  • Prior PPSV23 only: PCV20 ≥1 year after last PPSV23 dose 1
  • Prior PCV13 only: PCV20 ≥1 year after PCV13 dose 1
  • Prior PCV13 + 1 PPSV23: PCV20 ≥5 years after last pneumococcal vaccine 1

Chronic medical conditions (diabetes, chronic heart/lung/liver disease, alcoholism, smoking):

  • Vaccine-naïve: Single dose PCV20, OR PCV15 followed by PPSV23 ≥1 year later 1
  • Prior PPSV23 only: PCV20 ≥1 year after last PPSV23 dose 1
  • Prior PCV13 only: PCV20 ≥1 year after PCV13 dose 1

Previously Vaccinated Adults

Adults with Prior PCV13 and PPSV23 (Both Received at ≥65 Years)

  • Shared clinical decision-making regarding single dose of PCV20
  • If administered: Give ≥5 years after last pneumococcal vaccine 1
  • This is discretionary, not routinely recommended

Adults with Prior PCV13 at Any Age and PPSV23 Before Age 65

  • Single dose PCV20 ≥5 years after last pneumococcal vaccine 1
  • For immunocompromised: May give ≥8 weeks after PCV13 if PPSV23 route chosen instead 1

Key Timing Intervals

Critical intervals to memorize:

  • ≥1 year: Standard interval between PCV20 and prior PPSV23 or PCV13 in most scenarios 1, 3
  • ≥8 weeks: Shortened interval for immunocompromised patients between PCV15 and PPSV23, or between PCV13 and PPSV23 1, 3
  • ≥5 years: Required interval when giving PCV20 after both PCV13 and PPSV23 have been received 1

Contraindications

Absolute contraindications 1:

  • Severe allergic reaction (anaphylaxis) to any vaccine component
  • Severe allergic reaction to any diphtheria toxoid-containing vaccine (applies to all PCVs)

Precautions:

  • Consult package insert for complete precautions and warnings 1
  • Moderate to severe acute illness (defer vaccination)

Alternative Regimen: PCV15 + PPSV23

When PCV20 is unavailable or PCV15 is chosen:

  • PCV15 first, then PPSV23 at appropriate interval
  • Immunocompromised/CSF leak/cochlear implant: PPSV23 ≥8 weeks after PCV15 1, 3
  • All others: PPSV23 ≥1 year after PCV15 1, 3

Important note: If PCV20 is given, the series is complete—no additional PPSV23 needed 1. This is a major simplification advantage of PCV20 over the PCV15 + PPSV23 strategy.

Geographic Consideration

Western United States caveat: In communities where serotype 4 causes ≥30% of invasive pneumococcal disease, consider PCV20 (which contains serotype 4) over PCV21 (which does not) 1. PCV21 contains 8 additional serotypes not in PCV20 but lacks serotype 4, making regional epidemiology relevant to vaccine selection.

Common Pitfalls to Avoid

  1. Don't give PPSV23 after PCV20: PCV20 is a standalone vaccine; adding PPSV23 provides no additional benefit 1
  2. Don't ignore the 5-year interval: When patients have received both PCV13 and PPSV23, wait ≥5 years before PCV20 1
  3. Don't forget the 8-week option: Immunocompromised patients can receive accelerated schedules (8 weeks vs. 1 year) 1, 3
  4. Don't overlook the age expansion: As of 2024, all adults ≥50 years qualify for PCV20, not just ≥65 years 2
  5. Review vaccination status at age 65: For adults 19-64 who received vaccines for risk conditions, reassess recommendations when they turn 65 1

References

Related Questions

In a 73‑year‑old patient with unknown prior pneumococcal vaccination status, is there any contraindication to administering a second dose of pneumococcal conjugate vaccine 20‑valent (PCV20)?
If the 23‑valent pneumococcal polysaccharide vaccine (PPSV23) was administered on a specific date, does the patient still need the 15‑valent pneumococcal conjugate vaccine (PCV15)?
In a patient aged 65 years or older who is behind on vaccinations, should the 20‑valent pneumococcal conjugate vaccine (PCV20) be given as the preferred pneumococcal vaccine?
What is the recommended interval and method for administering both Prevnar 20 (20‑valent pneumococcal conjugate vaccine) and CAPVAXIVE (13‑valent pneumococcal conjugate vaccine) in the same adult patient?
In a patient scheduled for splenectomy who has already received PCV13 (13‑valent pneumococcal conjugate vaccine) and Hib (Haemophilus influenzae type b) vaccine, should PPSV23 (23‑valent pneumococcal polysaccharide vaccine) be administered after giving PCV20 (20‑valent pneumococcal conjugate vaccine)?
What antibiotic regimen is recommended for an adult intra‑abdominal abscess following laparoscopic appendectomy with cultures growing Pseudomonas species and gram‑positive cocci?
What is chimeric antigen receptor T‑cell (CAR‑T) therapy, how is it performed, what are its approved indications, and how are its toxicities such as cytokine release syndrome and immune effector cell‑associated neurotoxicity managed?
What are the recommended doses of magnesium, vitamin B12, and coenzyme Q10 for migraine prophylaxis in an adult patient without contraindications?
What surgical options are available for avascular necrosis of the scaphoid?
What is an occult fracture?
Will an MRI of the sacrum visualize the sacroiliac (SI) joints?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.